Invokana (canagliflozin) is a small molecule pharmaceutical. Canagliflozin was first approved as Invokana on 2013-03-29. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1. Invokana's patents are valid until 2031-05-11 (FDA).
|Indication||type 2 diabetes mellitus|
|Drug Class||Phlorozin derivatives, phenolic glycosides|